Tucker R M, Hanson L H, Brummer E, Stevens D A
Department of Medicine, Santa Clara Valley Medical Center and Institute for Medical Research, San Jose, California 95128.
Antimicrob Agents Chemother. 1989 Apr;33(4):573-5. doi: 10.1128/AAC.33.4.573.
ICI 195,739, a novel orally active triazole, proved 50 times as potent as ketoconazole, produced a clinical cure, and completely eradicated residual infection in a murine model of pulmonary blastomycosis. No other previously tested azole has shown similar activity. Fungicidal activity against Blastomyces dermatitidis was seen in vitro at concentrations 1/40 of those achieved in serum with protective doses.
ICI 195,739是一种新型口服活性三唑类药物,其效力被证明是酮康唑的50倍,在小鼠肺芽生菌病模型中产生了临床治愈效果,并完全根除了残留感染。此前测试的其他唑类药物均未显示出类似活性。在体外,对皮炎芽生菌的杀菌活性在浓度为血清中达到保护剂量时浓度的1/40时即可观察到。